newsfilter
← Latest News
Business Wire·

Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will discontinue enrollment